Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings results on February 23, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $0.46, beating the consensus estimate of $0.36 by $0.10 per share. Revenue came in at $875.0M, beating the estimate of $832.9M.
Biomarin Pharmaceutical's stock moved following the earnings release. The stock currently trades at $63.89 with a market capitalization of $10.2B.
